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The neuropathology of dementia may not be in the consciousness of clinicians while evaluating patients with
dementia. However, all clinicians should be aware of
the importance of neuropathology to dementia diagnosis.
For decades, b-amyloid deposited in senile plaques and
tau in neurofibrillary tangles has dominated the dementia
world, a-synuclein Lewy bodies being their sidekick. We
now have a new member of the inner circle.
In 2006, investigators from the University of
Pennsylvania reported that the transactive response
DNA binding protein 43 (TDP-43) was aberrantly
deposited in the brains of patients with amyotrophic
lateral sclerosis and frontotemporal lobar degeneration (FTLD).1 Little did they know how ubiquitous
pathologic TDP-43 really was. A year later, investigators from the Mayo Clinic showed that pathologic
TDP-43 was also present in the brains of patients
with the most common cause of dementia, Alzheimer
disease (AD).2 TDP-43 is a nucleotide binding protein that is present in the cell nuclei of normal brain
cells (figure) and helps to regulate RNA processing.
When TDP-43 is hyperphosphorylated, it accumulates in the cytoplasm of the cells (figure), a process
that is cytotoxic via gain- or loss-of-toxic function mechanisms. In AD, pathologic TDP-43 follows a stereotypical pattern of deposition that has been captured by the
TDP-43 in AD (TAD) staging scheme3: TDP-43 first
deposits in the amygdala (stage I), followed by hippocampus, limbic, temporal, and finally frontostriatum
(stage V). The presence and burden of TDP-43 deposition modifies clinical and radiologic phenotype and are
strongly associated with memory loss and hippocampal
atrophy,4,5 the 2 cardinal clinical features of AD. This
observed stereotypical pattern of deposition, and the clinical–pathologic correlation, suggest that TDP-43 should
join the inner circle of neurodegenerative misfolded proteins that now include b-amyloid, tau, and a-synuclein.
The sheer prevalence and influence of TDP-43
pathology are remarkable. This pathology occurs in
almost 60% of brains of patients with AD,4 and also
in 90% of cases of dementia associated with progressive neuronal loss and gliosis of the CA1 and subicular
regions of the hippocampus,6 a phenomenon known
as hippocampal sclerosis. Genetic risk factors for

hippocampal sclerosis in aged persons, recently characterized, reveal new insights into disease mechanisms. In
contrast to AD, APOE alleles are not implicated in hippocampal sclerosis, whereas alleles in the genes GRN,
TMEM106B, ABCC9, and KCNMB2 are linked to this
age-related hippocampal TDP-43 pathology.7–9
In this issue of Neurology®, Yu et al.10 from Rush
University Medical Center provide an important contribution related to the pathogenesis of TDP-43 pathology
in older persons. This study focuses on the transmembrane protein 106B gene (TMEM106B), a genetic risk
factor for the accumulation of abnormal TDP-43 in
FTLD, AD, and hippocampal sclerosis. In their study
of 544 autopsied participants from 2 community-based
studies of aging, the authors confirmed that common
variants in TMEM106B were indeed a distinct risk factor
for TDP-43 pathology in older patients. This observation again underscores the importance of pathologybased endophenotypes in studies related to genetic risk
factors. Capitalizing on their outstanding clinically and
pathologically evaluated research cohort, the study delves
into the complex interrelationships among comorbid
pathologies of older persons that include AD,
a-synucleinopathy, hippocampal sclerosis, and
TDP-43 pathology. The authors also aimed to better
understand the biological mechanisms underlying the
relationship between TMEM106B variants and the
deposition of TDP-43. This study breaks new ground
by exploring novel pathways involving DNA methylation and miRNA and mRNA expression. Their data and
analyses provide key support for the hypothesis that
TMEM106B variants are pathogenetically important
and exert their influence upstream of expression of
GRN, a gene that is also strongly implicated in FTLD
pathogenesis. A more theoretical mechanism is hypothesized related to increased inflammation of the brain
although the exact mechanism remains elusive. The
big picture is that heritable factors have strong influence
on late-life neurologic conditions. While daunting to
consider the importance of genes in dementia risk, this
story could have a silver lining, whereby therapeutic
intervention could occur at the preclinical stage in individuals genetically determined to be at risk of having
TDP-43-associated dementias.
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Figure

Pathologic transactive response DNA binding protein 43 inclusions in the human hippocampus

Transactive response DNA binding protein 43 (TDP-43) immunohistochemistry in the brain of a patient with dementia
shows normal nuclear TDP-43 staining in many cells, as well as pathologic TDP-43 in the cytoplasm of some cells (arrows).
Note the absence of normal nuclear TDP-43 staining in the cell when pathologic TDP-43 is observed in the cytoplasm. Image
taken from the dentate gyrus of the hippocampus.

There is no turning back from this developing
story of dementia due to multiple proteins and mixed
pathologies. It is the rule, and not the exception, for
older persons’ brains to harbor multiple comorbid
pathologies, and TDP-43 is a prime player. This
important new study highlights the importance of
better delineation of the currently indistinct boundary areas among AD, hippocampal sclerosis, and
TDP-43 pathology in advanced old age. Future studies are also needed to determine whether there are
other risk factors for the deposition of TDP-43, to
better understand the mechanism of TDP-43 transformation to pathologic TDP-43, for the development of biomarkers that can detect TDP-43
antemortem, and the ultimate goal of therapeutic
interventions that target pathologic TDP-43.
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